|
Research Area
|
|
Description
|
Immunology |
|
Biological Activity
|
|
Description
|
FTY720 (Fingolimod, Gilenya) is a S1P antagonist with IC50 of 0.033 nM. |
|
Targets
|
S1P receptor |
|
|
|
|
|
|
IC50 |
0.033 nM [1] |
|
|
|
|
|
|
In Vitro
|
The inhibitory effect of S1P is revered by various concentrations of FTY720, with IC50 effect of 173 nM. In addition, FTY720 (10 nM) alone exerts no effect on the expression of co-stimulatory molecules. FTY720 reverses the increased expression of HLA-I induced by S1P for both the percentages of cells and the MFI, upon comparing the effect of S1P to the effect of combining S1P with FTY720. [1] Medium and high-dose FTY720-P also enhances the levels of TGF-β1. TGF-β1 and Foxp3 mRNA expression are upregulated in the high-dose FTY720-P group. The proliferation of effector T cells is suppressed significantly in the medium and high-dose FTY720-P group at a Treg/Teff cell ratio of 1:1. At a ratio of 1:1, the proliferation of effector T cells is also suppressed in the high-dose FTY720 group. [2] |
|
In Vivo
|
FTY720 is effective in Ph+ but not Ph- ALL xenografts using an early disease model. FTY720 produces a significant reduction in disease burden in the Ph+ ALL xenografts using an early disease model. Ph+ human ALL xenografts responds to FTY720 with an 80±12% reduction in overall disease if treatment has been initiated early on. In contrast, treatment of mice with FTY720 does not result in reduced leukemia compared to controls using four separate human Ph- ALL xenografts. [3] |
|
Clinical Trials
|
FTY720 has enterd in a phase IV clinical trial in the treatment of multiple sclerosis anbd relapsing-remitting. |
|
Features
|
|
|
Combination Therapy
|
|
Description
|
Cyclosporine A (CsA) at doses of 0.3 mg/kg/day and 1 mg/kg/day has small effect on graft survival. Even at the lower CsA dose, adding 0.03 mg/kg FTY720 prolongs the MST from 7 days to 22 days. The next higher doses, 0.1 mg/kg/day and 0.3 mg/kg/day FTY720 prolongs MST to 32.5 days and 41 days, respectively. [4] FTY720 plus Avonex, Copaxone, Rebif, Betaseron or Extavia has entered in a phase IV clinical trial in the treatments of relapsing forms of multiple sclerosis. |
|
Protocol
|
|
Cell Assay
[1]
|
| Cell Lines |
Immature DCs |
| Concentrations |
10 nM |
| Incubation Time |
4 hours |
| Methods |
Immature DCs are left intact or are incubated with 2 μM S1P, 10 nM FTY720, 10 nM SEW2871 or the combinations of S1P with these drugs for 4 hours. As a control 1 μg/mL LPS is used. The cells are washed and incubated in a 96-well plate (v-bottom, 2 × 105 cells per well), washed again and resuspended in PBS buffer containing 0.1% sodium azide. They are labeled with 1 μg/mL FITC-conjugated mouse anti-human CD80, 1 μg/mL FITC-conjugated mouse anti-human CD83, 1 μg/mL FITC-conjugated mouse anti-human CD86, 1 μg/mL FITC-conjugated mouse anti-human HLA-class I, 1 μg/mL FITC-conjugated mouse anti-human HLA-DR, 1 μg/mL FITC-conjugated mouse anti-human HLA-E, or 1 μg/mL FITC-conjugated mouse IgG as a control. The cells are washed twice, and examined in the flow cytometer. Markers are set according to the isotype control FITC-conjugated mouse IgG. To stain NK cells with antibodies for various NK cell activating receptors, they are either left untreated or incubated with 2 μM S1P for 4 hours, washed and stained with 1 μg/mL PE-conjugated mouse anti-human NKp30 (CD337), 1 μg/mL PE-conjugated mouse anti-human NKp44 (CD336), 1 μg/mL PE-conjugated mouse anti-human NKG2D (CD314), or as a control 1 μg/mL PE-conjugated mouse IgG1, for 45 min at 4 °C. NK cells are also stained with 1 μg/mL FITC-conjugated anti-killer inhibitory receptor (KIR)/CD158 antibody which recognizes KIR2DL2, KIR2DL3, KIR2DS2 and KIR2DS4, and as a control with FITC-conjugated mouse IgG. The cells are washed twice, and examined in the flow cytometer. Markers are set according to the isotype control PE-conjugated or FITC-conjugated mouse IgG. |
|
Animal Study
[3]
|
| Animal Models |
NOD/SCIDγc?/? mice bearing ALL cells. |
| Formulation |
2% ethanol or saline |
| Doses |
5 mg/kg/day, 10 mg/kg/day |
| Administration |
Administered via i.p. |
|
References |
|
[1] Rolin J, et al. Cancer Immunol Immunother. 2010, 59(4), 575-586.
|
|
[2] Liu Y, et al. Int J Mol Med. 2012, 30(1), 211-219.
|
|
[3] Wallington-Beddoe CT, et al. PLoS One. 2012, 7(5), e36429.
|
|
[4] Nikolova Z, et al. Transpl Immunol. 2001, 8(4), 267-277.
|
|